MorningMed is a community of 814,300 medical professionals

We're a place where medical professionals share news and other news items to help their peers stay up to date

All articles tagged: Allergy, unspecified, initial encounter (T78.40XA)

HealthDay 02 July at 10.50 PM

Allergy-Related Psychological Distress Common

Psychological distress related to food allergies (FA) is common globally, according to a study published online June 21 in Allergy.Rebecca C. Knibb, Ph.D., from Aston University in Birmingham, England, and colleagues assessed psychological distress and service use among adults, caregivers, and children with FA. The global survey in

Evalytics 26 February at 09.37 PM

The FDA Approval of Xolair Injections: Revolutionizing Food Allergy Treatment

The FDA approved Xolair injections for severe food allergies like peanuts and eggs, a breakthrough in allergy treatment, providing relief to many.

Evalytics 19 February at 02.46 PM

FDA expands use of asthma drug Xolair to treat severe food allergies

The article discusses a study showing promising results for treating peanut allergies with Xolair, an asthma medication. Xolair was found to reduce allergic reactions in children, offering potential relief from severe peanut allergies. Researchers hope this could lead to a new treatment option for peanut allergies in the future.

HealthDay 20 January at 12.01 AM

Study IDs Risks to Offspring Associated With Prenatal Opioid Exposure

Prenatal opioid exposure (POE) is associated with an increased risk for infection, eczema and dermatitis, and asthma in offspring, but it is not linked to allergies or anaphylaxis, according to a study published online Jan. 17 in JAMA Network Open.Erin Kelty, Ph.D., from the University of Western Australia in Crawley, and colleagues com

HealthDay 09 November at 04.08 PM

FDA Approves New Diet Drug Zepbound, a Version of the Diabetes Med Mounjaro

A second injectable diabetes drug has been approved for weight loss in overweight and obese adults, the U.S. Food and Drug Administration announced Wednesday. The weight-loss drug Zepbound contains the same active ingredient, tirzepatide, as the diabetes drug Mounjaro.Zepbound works by activating hormone receptors in the body to reduce appetite